Scientists track mystery Drug's journey through healthy volunteers
NCT ID NCT07644442
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study gave 6 healthy Chinese men a single oral dose of a radiolabeled drug called HMPL-453 to see how it is absorbed, broken down, and eliminated. Researchers measured radioactivity in blood, urine, and feces over time. The goal was not to treat any disease but to understand the drug's path in the body, which is essential for planning future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HMPL-453 (a drug being studied, given as a single oral dose with a radioactive tracer)
- What this could lead to
- If successful, this study will show how HMPL-453 moves through and leaves the body, helping design future trials for diseases it may treat.
- What could go wrong
- This is a very early, small study in just 6 healthy men, not patients. It only tracks the drug's path in the body and does not test if it works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASS BALANCE STUDY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)
Jinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.